Hybritech Incorporated

Mayo Foundation for Medical Education and Research

Other

Hyrbritech Incorporated

Mohammad Saeed Saedi

Stephen D Mikolajczyk

Abhay Kumar

Donald J Tindall

Robert L Wolfert

Harry G Rittenhouse

Charles Y Young

Kevin Slawin

Kristine Kuus-Reichel

Charles Y F Young

Inactive precursor forms of PSA (pPSA) have been identified to exist in serum and tissues of patients with prostate cancer. Antibodies specific for pPSA are provided. Methods for detecting inactive precursors of PSA in human physiological fluid and tissues are also provided, as well as diagnostic kits and methods useful in the diagnosis and management of prostate cancer.

Forms of prostate specific antigens and methods for their detection

Prostate cancer is detected by determining the presence of hK2 RNA in a physiological sample.

Method for detection of micrometastatic prostate cancer

The present invention provides a novel complex of hK2 and PI-6 and methods of using the novel complex and its constituents. The novel complexes of hK2 and PI-6 of the present invention and the PI-6 exist at an elevated level in prostate cancer tissues. PI-6 also exists at an elevated level in other types of cancer cells. Therefore, the hK2-PI6 complexes and PI-6 of the present invention may be used as a serum marker for detecting cancers, particularly prostate cancer. They may also be used as an immunohistological marker to detect prostate cancer tissues. In accordance with the present invention, the hK2-PI6 complexes of the present invention may be detected in patient tissue samples by immunohistochemical and/or in patient fluid samples by in vitro immunoassay procedures. Diagnostic methods for detecting the existence of prostate cancer is also provided.

Complex of human kallikrein 2 (hK2) and protease inhibitor-6 (PI-6) in prostate tumor tissue and methods of using the complex and its constituents

The present invention provides a novel complex of hK2 and PI-6 and methods of using the novel complex. The novel complexes of hK2 and PI-6 of the present invention exist at an elevated level in prostate cancer tissues. Therefore, the hK2-PI6 complexes of the present invention may be used as a serum marker for detecting prostate cancer. They may also be used as an immunohistological marker to detect prostate cancer tissues. In accordance with the present invention, the hK2-PI6 complexes of the present invention may be detected in patient tissue samples by immunohistochemical and/or in patient fluid samples by in vitro immunoassay procedures. Diagnostic kits and diagnostic methods for detecting the existence of prostate cancer are also provided.

Complex of human kallikrein 2 (hK2) and protease inhibitor-6 (PI-6) in prostate tumor tissue and methods of using the complex

An isolated, purified variant hK2 polypeptide useful in preparing immunogenic compositions and vaccines is provided. The variant hK2 polypeptides are more stable to purification than wild type mature hK2 polypeptide.

Stable variant hK2 polypeptide

An isolated, substantially homogenous pre-pro, pro or mature hK2 polypeptide is provided as well as biologically active variants or subunits thereof, including a biologically active variant pre-pro hK2 polypeptide having SEQ ID NO:19.

Recombinant hK2 polypeptide

Isolated nucleic acid molecules encoding variant hK2 polypeptides and fragments thereof, as well as expression cassettes and host cells comprising said nucleic acid molecules, are provided. Also provided is a method to express a nucleic acid molecule encoding a variant hK2 polypeptide.

Growing community of inventors

San Diego, CA, United States of America

Mohammad Saeed Saedi